Welcome to our dedicated page for PhaseBio Pharmaceuticals news (Ticker: PHAS), a resource for investors and traders seeking the latest updates and insights on PhaseBio Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PhaseBio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PhaseBio Pharmaceuticals's position in the market.
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The company aims to sell its bentracimab program assets through a structured auction process. A large pharmaceutical company has entered into a non-binding agreement to serve as the stalking horse bidder, proposing an upfront payment of $40 million and additional milestone payments totaling $60 million. JMB Capital Partners has provided a $15 million financing commitment to support PhaseBio during this process.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) reported its Q2 2022 results, highlighting significant progress in its clinical development. Following a successful FDA pre-BLA meeting, PhaseBio aims to submit the BLA for its lead product, bentracimab, by Q4 2022. The company is also advancing its aldosterone synthase inhibitor, PB6440, with an IND filing expected in H1 2023 and human trials slated for mid-2023. Financially, PhaseBio's cash decreased to $7.8 million, and it reported a net loss of $16.7 million, down from $28.7 million year-over-year.
PhaseBio Pharmaceuticals (PHAS) reported a significant Q1 2022 with an $11.1 million net loss, an improvement from $27.4 million the previous year. The company successfully completed a Type B pre-BLA meeting with the U.S. FDA for bentracimab, planning to submit the BLA in Q4 2022. Positive Phase 2b trial results for bentracimab were presented at ACC.22, showing effective restoration of platelet function. PhaseBio completed its Process Performance Qualification for bentracimab, ensuring readiness for commercial manufacturing. Cash on hand was $18.7 million, down from $41.8 million at year-end 2021.
PhaseBio Pharmaceuticals announced the successful completion of a Pre-BLA Meeting with the FDA for bentracimab, aimed at reversing ticagrelor's antiplatelet effects. The FDA is open to a BLA submission based on data from 25-30 uncontrolled bleeding patients alongside surgical data. Currently, 35 uncontrolled bleeding patients are enrolled in the Phase 3 REVERSE-IT trial. The company plans to submit the BLA by early Q4 2022 and will continue to enroll patients to meet post-approval requirements.
PhaseBio Pharmaceuticals (NASDAQ: PHAS), a biopharmaceutical company focused on cardiovascular therapies, announced that CFO John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on April 14, 2022, from 1:30 to 2:10 PM ET. The event will be held virtually, and interested parties can access the live and archived webcasts on the company's website. PhaseBio is known for its novel pipeline, including bentracimab and PB6440, aimed at improving treatment outcomes in cardiovascular diseases.
PhaseBio Pharmaceuticals announced complete results from its Phase 2b trial of bentracimab, presented on
PhaseBio Pharmaceuticals (Nasdaq: PHAS) announced significant clinical advancements in its bentracimab program, achieving positive results from both the Phase 2b trial and interim analysis of the ongoing Phase 3 REVERSE-IT trial. The company is on track to submit a Biologics License Application (BLA) for bentracimab in mid-2022. Additionally, PhaseBio plans to submit an Investigational New Drug (IND) application for PB6440 for resistant hypertension in the second half of 2022. Financially, the company reported a net loss of $131.1 million for the full year 2021, up from $98.6 million in 2020, while cash equivalents improved to $41.8 million.
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) has completed the Process Performance Qualification (PPQ) for its lead drug candidate, bentracimab. This essential step involves validating the manufacturing process and ensuring consistency for commercial scale production. The company is on track to submit its Biologics License Application (BLA) to the FDA in mid-2022. Bentracimab is in late-stage clinical development, with promising results from the ongoing Phase 3 REVERSE-IT trial aimed at reversing the antiplatelet effects of ticagrelor in patients facing uncontrolled bleeding.
PhaseBio Pharmaceuticals (NASDAQ: PHAS) announced that CEO Jonathan P. Mow will participate in Cowen's 42nd Annual Health Care Conference on March 8, 2022, from 12:50 PM to 1:50 PM ET. The event is virtual, and interested individuals can access the live and archived webcasts on the company's website. PhaseBio focuses on developing therapies for cardiovascular conditions, with key products in its pipeline including bentracimab, pemziviptadil, and PB6440. For more details, visit www.phasebio.com.
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced the acceptance of their Phase 2b trial results for bentracimab for presentation at the American College of Cardiology Annual Scientific Session on April 2, 2022. The trial, involving 150 subjects, demonstrated the efficacy of bentracimab in reversing the antiplatelet effects of ticagrelor. The company plans to submit a Biologics License Application (BLA) to the FDA in mid-2022 as part of the ongoing development process for this potentially life-saving therapy.
